{"id":"NCT02265913","sponsor":"Padagis LLC","briefTitle":"Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-06","primaryCompletion":"2016-04-27","completion":"2017-11-21","firstPosted":"2014-10-16","resultsPosted":"2021-01-05","lastUpdate":"2021-10-22"},"enrollment":4076,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Herpes Labialis"],"interventions":[{"type":"DRUG","name":"Acyclovir 5 percent (Perrigo)","otherNames":["Perrigo product"]},{"type":"DRUG","name":"Acyclovir 5 percent (Reference)","otherNames":["Reference Listed Drug Product"]},{"type":"DRUG","name":"Placebo cream","otherNames":[]}],"arms":[{"label":"Test Product","type":"EXPERIMENTAL"},{"label":"Reference Product","type":"ACTIVE_COMPARATOR"},{"label":"Placebo Product","type":"PLACEBO_COMPARATOR"}],"summary":"To compare safety and efficacy of Perrigo's antiviral drug product compared to an FDA approved antiviral drug product in the treatment of cold sores.","primaryOutcome":{"measure":"Lesion Healing","timeFrame":"up to 21 days","effectByArm":[{"arm":"Test Product","deltaMin":107.47,"sd":80.66},{"arm":"Reference Product","deltaMin":110.08,"sd":82.84},{"arm":"Placebo Product","deltaMin":112.41,"sd":83.467}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":1357},"commonTop":[]}}